Repeat drug-coated balloon angioplasty for femoropopliteal lesions: 12-month results from a retrospective observational study

• Published in: CVIR endovascular 2024-02, Vol.7 (1), p.24-24, Article 24
• Main Authors: Haraguchi, Takuya, Tsujimoto, Masanaga, Kashima, Yoshifumi, Sato, Katsuhiko, Fujita, Tsutomu
• Format: Article
• Language: English
• Subjects: Angioplasty; Balloon angioplasty; Calcification; Drug-coated balloon; Imaging; Interventional Radiology; Medicine; Medicine & Public Health; Original Article; Patency; Radiology; Restenosis; Revascularization
• ISSN: 2520-8934; 2520-8934
• DOI: 10.1186/s42155-024-00434-w

Background The clinical implications of restenosis after drug-coated balloon (DCB) treatment remain unclear. We compared the clinical outcomes between DCB angioplasty for restenosis and de novo femoropopliteal artery lesions. This single-center retrospective study included 571 patients (737 limbs) who underwent either repeat (54 patients, 64 limbs) or de novo DCB (517 patients, 673 limbs) without bailout stenting. After propensity score matching, 49 matched pairs were analyzed. The primary endpoint was the 1-year primary patency, with secondary endpoints including the freedom from target lesion revascularization (TLR), major adverse limb events (MALE), and early restenosis. Predictors of restenosis were identified using multivariable Cox regression analysis. Results The repeat-DCB group displayed significantly lower rates of 1-year primary patency and freedom from TLR compared to those of the de novo-DCB group (50.1% vs. 77.4%, p  = 0.029 and 54.9% vs. 83.6%, p  = 0.0.44, respectively). No significant differences were observed in early restenosis or MALE (10.7% vs. 5.9%, p  = 0.455 and 48.3% vs. 73.4%, p  = 0.055, respectively). Restenosis after DCB angioplasty was associated with repeat DCB (hazard ratio [HR], 5.13; 95% confidence interval [CI], 1.43–18.4; p  = 0.012) and small vessel size of